These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 17069528)

  • 1. Drug target interaction of tubulin-binding drugs in cancer therapy.
    Sengupta S; Thomas SA
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1433-47. PubMed ID: 17069528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microtubules: a dynamic target in cancer therapy.
    Pasquier E; Kavallaris M
    IUBMB Life; 2008 Mar; 60(3):165-70. PubMed ID: 18380008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tubulin and microtubules as targets for anticancer drugs.
    Hadfield JA; Ducki S; Hirst N; McGown AT
    Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorescence spectroscopic methods to analyze drug-tubulin interactions.
    Bhattacharyya B; Kapoor S; Panda D
    Methods Cell Biol; 2010; 95():301-29. PubMed ID: 20466142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microtubule alterations and resistance to tubulin-binding agents (review).
    Drukman S; Kavallaris M
    Int J Oncol; 2002 Sep; 21(3):621-8. PubMed ID: 12168109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity.
    Buey RM; Barasoain I; Jackson E; Meyer A; Giannakakou P; Paterson I; Mooberry S; Andreu JM; Díaz JF
    Chem Biol; 2005 Dec; 12(12):1269-79. PubMed ID: 16356844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on tubulin-binding agents.
    Attard G; Greystoke A; Kaye S; De Bono J
    Pathol Biol (Paris); 2006 Mar; 54(2):72-84. PubMed ID: 16545633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-anticancer drugs encapsulated in the micelle: a novel chemotherapy to cancer.
    Liu P; Wang B; Weili Qiao JL
    Med Hypotheses; 2008 Sep; 71(3):379-81. PubMed ID: 18556140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Target selectivity of anticancer drugs].
    Fattoruso SI; Di Lauro L; Conti F; Amodio A; Lopez M
    Clin Ter; 2008; 159(3):189-206. PubMed ID: 18594750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The polyamine transport system as a target for anticancer drug development.
    Palmer AJ; Wallace HM
    Amino Acids; 2010 Feb; 38(2):415-22. PubMed ID: 19956998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tubulin: an example of targeted chemotherapy.
    Seligmann J; Twelves C
    Future Med Chem; 2013 Mar; 5(3):339-52. PubMed ID: 23464522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of tubulin drug binding sites and prediction of relative differences in binding affinities to tubulin isotypes using digital signal processing.
    Chen K; Huzil JT; Freedman H; Ramachandran P; Antoniou A; Tuszynski JA; Kurgan L
    J Mol Graph Model; 2008 Nov; 27(4):497-505. PubMed ID: 18951052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-Phenyl-N'-(2-chloroethyl)ureas (CEU) as potential antineoplastic agents. Part 2: role of omega-hydroxyl group in the covalent binding to beta-tubulin.
    Fortin S; Moreau E; Patenaude A; Desjardins M; Lacroix J; Rousseau JL; C-Gaudreault R
    Bioorg Med Chem; 2007 Feb; 15(3):1430-8. PubMed ID: 17118664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular beta-tubulin/chaperonin containing TCP1-beta complex serves as a novel chemotherapeutic target against drug-resistant tumors.
    Lin YF; Tsai WP; Liu HG; Liang PH
    Cancer Res; 2009 Sep; 69(17):6879-88. PubMed ID: 19690144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoscale delivery systems for multiple drug combinations in cancer.
    Cao Y; Wang B; Lou D; Wang Y; Hao S; Zhang L
    Future Oncol; 2011 Nov; 7(11):1347-57. PubMed ID: 22044207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin.
    Bhattacharyya B; Panda D; Gupta S; Banerjee M
    Med Res Rev; 2008 Jan; 28(1):155-83. PubMed ID: 17464966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for treating cancers caused by multiple genome abnormalities: from concepts to cures?
    Workman P
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1410-5. PubMed ID: 14763125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microtubule assembly dynamics: an attractive target for anticancer drugs.
    Singh P; Rathinasamy K; Mohan R; Panda D
    IUBMB Life; 2008 Jun; 60(6):368-75. PubMed ID: 18384115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible binding site for paclitaxel at microtubule pores.
    Magnani M; Maccari G; Andreu JM; Díaz JF; Botta M
    FEBS J; 2009 May; 276(10):2701-12. PubMed ID: 19459933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dietary antioxidant curcumin inhibits microtubule assembly through tubulin binding.
    Gupta KK; Bharne SS; Rathinasamy K; Naik NR; Panda D
    FEBS J; 2006 Dec; 273(23):5320-32. PubMed ID: 17069615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.